The Fosun subsidiary is paying the upfront fee, committing up to 1.12 billion yuan ($166 million) in milestones and agreeing ...
Roche’s investigational KRAS G12C inhibitor has beaten Amgen’s Lumakras and Bristol Myers Squibb’s Krazati in a phase 3 trial ...
AbbVie has struck a deal to buy Apogee Therapeutics for $10.9 b | AbbVie has struck a deal to buy Apogee Therapeutics for $10 ...
Insilico Medicine has signed a deal worth up to $600 million with Takeda to collaborate on asset discovery across the Japan Big Pharma's therapeutic areas of interest. | Insilico Medicine has signed ...
Insillico Medicine and SK Biopharmaceuticals have teamed up on an AI-enabled search for drug candidates targeting neuroimmune ...
Five months after Corxel Pharmaceuticals reeled in hundreds of millions of dollars to support further development of its oral ...
When writing a blockbuster movie script, screenplay writers are sure to include all the essential elements of a hit | The ...
The beleaguered genomic medicine biotech Sangamo has traveled a rough road lately, with recent years | Eli Lilly and Astellas ...
Pfizer’s high-stakes bet on antibody-drug conjugates (ADCs) has hit a speed bump. | Pfizer announced Monday that sigvotatug ...
United Therapeutics has paid $140 million to buy Thymmune Therapeutics for preclinical regenerative cell therapies focused on the thymus.
Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s oncology deal with Innovent Biologics took less than five ...
With pharma heavyweights clashing against one another and reeling in major sales in the ulcerative colitis (UC) | Merck is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results